If you didn't find what you were looking for, try a new search!
The American Academy of Sleep Medicine Weekly Insider keeps members informed about current AASM initiatives and the latest developments in the field of sleep medicine. Impact of Philips leaving the US market An article in the August issue of JCSM examines the impact of [...]
Jazz Pharmaceuticals | IEP Platinum Level Sponsor For many, the burden of IH goes far beyond excessive daytime sleepiness (EDS) and living daily life can be a struggle. Symptoms of IH include EDS, sleep inertia, cognitive impairment, long unrefreshing naps, and prolonged sleep time. [...]
The American Academy of Sleep Medicine Weekly Insider keeps members informed about current AASM initiatives and the latest developments in the field of sleep medicine. Cancer risk associated with CPAP An analysis of 2,571 patient injuries associated with CPAP devices from 2014 to 2021 [...]
DARIEN, IL – May 21, 2021 –Don’t miss your opportunity to join leading scientists and sleep clinicians from around the globe at the world’s largest meeting for sleep and circadian science. Virtual SLEEP 2021, the 35th annual meeting of the Associated Professional Sleep Societies [...]
Summary Users can customize sunset and sunrise light intensities and duration, alarm, snooze, and sound features. To assist sleep onset, seven light-guided breathing programs also are available using the touch display. Users also can select nature sounds, music, or an FM radio station to [...]
The American Academy of Sleep Medicine Weekly Insider keeps members informed about current AASM initiatives and the latest developments in the field of sleep medicine. From AASM President Dr. Kannan Ramar During moments of crisis, we can either continue to despair and bemoan the [...]
FDA reclassifies PAP as a Class II device The FDA has issued a final rule, “Classification of the Positive Airway Pressure Delivery System,” effective Oct. 19, 2018, that reclassifies the PAP delivery system, moving it from class III into class II. PAP continues to [...]
Patients with obstructive sleep apnea often report that they feel like “a new person” after beginning treatment with continuous positive airway pressure therapy. A new study in the Jan. 1 issue of the journal SLEEP provides objective evidence to support these anecdotal reports, showing that three weeks of CPAP therapy significantly reduced fatigue and increased energy in patients with OSA.
Jazz Pharmaceuticals | IEP Platinum Level Sponsor Learn more from idiopathic hypersomnia experts about the multiple symptoms that manifest in patients living with this unique 24-hour sleep disorder. In this paper you will find their perspectives on the role of these symptoms in [...]
By Jennifer Gibson, AASM Communications Manager Central disorders of hypersomnolence are among the most difficult sleep conditions to diagnose. Many patients struggle for years before getting an accurate diagnosis, and they often feel alone in their battle. Patients report undergoing numerous sleep studies and [...]
By Lynn Marie Trotti, MD, MSc, Treatment of Central Disorders of Hypersomnolence Guideline Task Force Reflecting advancements in treatment options, the American Academy of Sleep Medicine recently published an updated clinical practice guideline on the treatment of central disorders of hypersomnolence. The guideline includes [...]
On Aug. 12, 2021, Jazz Pharmaceuticals announced the FDA approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults. About Xywav Xywav, also known as JZP258, is a lower-sodium oxybate treatment taken at night to help treat multiple symptoms of IH, [...]
